Finanzen von Braveheart Bio, Inc. (BRVE)BRVEBraveheart Bio, Inc.

In the context of the broader market, BRVE competes directly with industry leaders such as BHVN and ZYME. With a market capitalization of $1.80B, it holds a leading position in the sector. When comparing efficiency, BRVE's gross margin of N/A stands against BHVN's N/A and ZYME's 100.00%. Such benchmarking helps identify whether Braveheart Bio, Inc. is trading at a premium or discount relative to its financial performance.

Braveheart Bio reported a net loss of $18.60 million for Q2 2026, significantly higher than the $0.38 million loss in Q2 2025. The EPS for Q2 2026 was -2.51, reflecting a substantial decline in profitability.